Grifols, member of CataloniaBio, reached an agreement to acquire a 44% stake in GigaGen Inc., for 35 million dollars in cash. GigaGen is a biopharmaceutical company based in San Francisco (California) specialized in the discovery and development of pre-clinical biotherapeutics.

GigaGen currently has several projects under way in collaboration with various pharmaceutical companies. The company also heads a range of in-house research projects, including the development of world's first recombinant intravenous immunoglobulin and a diverse portfolio of immuno-oncology therapies.

This transaction allows Grifols to further strengthen its R&D+i portfolio by acquiring holdings in research projects and companies that complement its activity and hold the potential of generating high added value.

More information is available on the Grifols website.

Photo: GigaGen Inc